Veymont Participations
Lyon, France8
818K
8
0.62
1
1
- Areas of investment
Investor highlights
- Stage focus
Discover reliable insights
Find relevant VC investors, identify key contacts and secure funding opportunities.
Investments analytics
Analytics
- Total investments
- 8
- Lead investments
- 1
- Exits
- 1
- Rounds per year
- 0.62
- Investments by industry
- Commercial (1)
- Communities (1)
- Parks (1)
- Leisure (1)
- Software (1) Show 18 more
- Investments by region
- France (8)
- Peak activity year
- 2014
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 8
- Group Appearance index
- 0.75
- Avg. company exit year
- 8
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| Previa Medical | 16 Feb 2023 | Artificial Intelligence, Health Care, Electronic Health Record (EHR), Medical | Seed | 2M | Lyon, Rhone-Alpes, France |
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| Protego Biopharma | Jan 12, 2025 | Amyloid Diseases, Biotechnology, Protein Folding, Small Molecule Therapeutics | Unknown | 130000000 USD |  San Diego, California |
| āshibio | Jun 20, 2024 | Biotechnology, Bone and Connective Tissue Disorders, Therapeutics | Early stage | 40000000 USD | Brisbane, California |
| Crossbow Therapeutics | Nov 7, 2023 | Antibody Therapies, Biotechnology, Cancer Therapies, Cancer Treatment, Immunotherapies | Early stage | 80000000 USD | Cambridge, Massachusetts |
| Deka Biosciences | Sep 28, 2023 | Biotech, Cytokine Therapies, Pharmacodynamics, Pharmacokinetics, Pharmacokinetics / Pharmacodynamics, Precision Medicine | Mid stage | 20000000 USD | Germantown, Maryland |
| ReNAgade Therapeutics | May 24, 2023 | Biotechnology, Circular RNA Technology, Gene Editing, RNA Delivery Platforms, RNA Medicines | Early stage | 300000000 USD | Cambridge, Massachusetts |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.